 |
| Typhoid Fever Vaccines Market |
Typhoid fever vaccines are immunization vaccines administered to prevent typhoid fever caused by Salmonella Typhi bacteria. Typhoid fever is a life-threatening illness and fatal if not treated. The vaccines available in the market are alive attenuated oral Ty21a vaccine (Vivotif), injectable Typhoid Vi polysaccharide vaccine (Typhim Vi), and conjugate typhoid vaccine (BivVCTC025). The oral Ty21a and injectable Typhim Vi vaccines provide around 70% protection for 2-3 years. However, the conjugated Typhoid vaccine offers long term protection of over 90% for 5 years. Growing immunity initiatives by governments and international organizations to eliminate typhoid as a public health problem are majorly driving the demand for effective typhoid fever vaccines.
The Global Typhoid Fever Vaccines Market is estimated to be valued at US$ 454.2 Bn in 2024 and is expected to
exhibit a CAGR of 14% over the
forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Typhoid Fever Vaccines are Linde Plc, Air Liquide,
Engie, Uniper Se, Air Products Inc, Clean Hydrogen System, Cummins Inc.,
Toshiba Energy Systems & Solutions Corporation, Nel Asa, and Sgh2 Energy.
There is an increase in research initiatives for better vaccines in terms of
higher efficacy and longer duration of protection. Organizations like WHO aim
to introduce universal access to typhoid conjugate vaccines in endemic
countries by 2025.
Major companies are expanding their operations in emerging Asian and African
countries owing to a significant disease burden. Strategic partnerships and
acquisitions will further aid companies in strengthening global market
presence.
Market drivers
Growing incidence of typhoid cases worldwide primarily drives the typhoid fever
vaccines market. According to WHO, over 11 million typhoid cases and more than
100,000 deaths are reported globally each year, majority in developing regions
lacking proper sanitation and access to clean water. This has triggered global
campaigns for effective prevention through vaccination programs.
Strong funding support from international organizations towards large scale
vaccination drives in endemic areas also favor market growth. Government
initiatives in developing nations to introduce typhoid vaccines in routine
immunization programs will further boost revenues.
Market restraints
High costs associated with development and production of typhoid conjugate
vaccines remain a major restraint for widespread adoption. Also, the complex
multi-dose vaccination schedule acts as a non-compliance challenge. Limited awareness
regarding vaccine benefits particularly in remote regions also hinders market
growth to some extent.
Segment Analysis
Typhoid Typhoid
Fever Vaccines Market Growth can be segmented based on Type into live
attenuated vaccine and capsular polysaccharide vaccines. The live attenuated
vaccine segment dominates the market as it offers lifelong protection from the
disease with just one oral dose. Hence, it is preferred for mass immunization
programs in endemic regions.
Global Analysis
Regionally, Asia Pacific accounts for the fastest growth in the typhoid fever
vaccines market during the forecast period. This is attributed to large
population base, growing awareness regarding preventive healthcare, and
increasing government initiatives for immunization in countries like India and
China. Many developing nations in Asia are highly endemic for typhoid fever due
to poor sanitation and lack of clean drinking water. This makes mass
immunization programs crucial in the region for preventing the spread of the
disease. North America is expected to be the second largest market owing to
rising awareness level and established healthcare infrastructure.
0 Comments